Epigenetic therapeutics such as HDAC-inhibitors, which are used clinically with a well characterized safety profile in a number of clinical trials in AML (48–50), represent attractive candidates for synergistic combinations with immunotherapies. Here, HDAC9 is linked to acute myeloid leukemia.